Home > Insider Trading > Filing (0001209191-10-050700)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1409012	Abraxis Bioscience Inc.	ABII	Pharmaceutical Preparations (2834)	300431735

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
816284	Celgene Corp /De/	86 Morris Avenue Summit NJ 07901		No	No	Yes	No
1496222	Artistry Acquisition Corp.	86 Morris Avenue Summit NJ 07901		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2010-10-15	40,735,300	$0.00	100	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Footnotes

This form is a joint filing by Celgene Corporation, a Delaware corporation ("Parent") and Artistry Acquisition Corp., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub").
This Form 4 relates to shares of common stock, par value $0.001 per share (the "Shares"), of Abraxis BioScience, Inc., a Delaware corporation ("Abraxis").
Amount includes all the Shares acquired pursuant to the Agreement and Plan of Merger, dated as of June 30, 2010 (the "Merger Agreement"), by and among Parent, Merger Sub and Abraxis. Merger Sub was merged with and into Abraxis with Abraxis surviving the merger as a wholly-owned subsidiary of Parent (the "Merger") upon the terms and subject to the conditions of the Merger Agreement. At the effective time of the Merger, all Shares were cancelled and ceased to exist.
Abraxis stockholders received, for each Share that they owned: (a) $58.00 in cash, without interest, (b) 0.2617 of a share of common stock of Parent, and (c) one contingent value right issued by Parent.
Prior to the Merger, Parent held 100 shares of the common stock, par value $0.001 per share, of Merger Sub (the "Merger Sub Shares"), which represented all of the issued and outstanding capital stock of Merger Sub. At the effective time of the Merger, each Merger Sub Share was converted into one share of common stock, par value $0.001 per share, of Abraxis, as the surviving corporation of the Merger, and as a result Parent acquired 100% of the equity interest of Abraxis.